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TRUJILLO, K. A. AND H. AKIL. The NMDA receptor antagonist MK-801 increases morphine catalepsy and lethality. PHAR- 
MACOL BIOCHEM BEHAV 38(3) 673-675, 1991.--Interactions between excitatory amino acids and opioids were examined by 
studying the ability of the noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist MK-801 to affect morphine catalepsy 
and lethality. MK-801 (0.3 mg/kg) reduced the EDso for morphine-induced catalepsy from approximately 30 mg/kg to less than 10 
mg/kg, and reduced the LDso for morphine from approximately 100 mg/kg to approximately l0 mg/kg. Lower doses of MK-801 
did not affect morphine catalepsy or lethality. MK-801, in the absence of morphine, produced no catalepsy or lethality at doses up 
to 3.0 mg/kg; at 0.3 mg/kg MK-801 caused weaving, body rolling and ataxia, as previously described, while at 3.0 mg/kg animals 
appeared to lose muscle tone, becoming limp. These results demonstrate that blockade of NMDA receptors can dramatically poten- 
tiate morphine catalepsy and lethality, and suggest a potential dangerous interaction with opioids in the clinical use of NMDA re- 
ceptor antagonists. 
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EXCITATORY amino acids and their receptors are widespread 
throughout the central nervous system, and have been the subject 
of considerable recent attention. Studies using excitatory amino 
acid antagonists have found these neurotransmitters to be impor- 
tant in a variety of behavioral and neurological phenomena, rang- 
ing from learning and memory to brain damage (4,16). As a result 
of their many effects, excitatory amino acid antagonists have been 
suggested to be of potential use in several clinical situations in- 
cluding brain damage (4,16), seizure disorders (4,16), anxiety 
(4,16), migraine (16) and Parkinson's disease (8,13). The broad 
distribution of excitatory amino acid systems, and the broad range 
of effects of their antagonists, suggest the possibility that these 
drugs may produce harmful effects in addition to their beneficial 
effects, either by acting alone, or by interacting with other sub- 
stances. Such actions could limit the clinical usefulness of exci- 
tatory amino acid antagonists. 
Opiate compounds are clinically very important. These agents 
are the drugs of choice for treating severe or intractable pain re- 
suiting from trauma or disease. At moderate doses, opiates de- 
crease pain responsiveness without affecting consciousness or 
movement. However, at high doses, these drugs produce muscu- 
lar rigidity in humans and catalepsy in rats, and eventually pro- 
duce death by respiratory depression. In the course of examining 
interactions between the prototypical opiate morphine and the ex- 
citatory amino acid antagonist MK-801 we have found that MK- 
801 dramatically increases morphine catalepsy and lethality. 
METHOD 
Subjects were 160 adult male Sprague-Dawley rats (n=  3 to 
24 per group). Animals were administered saline or (+)-MK-801 
maleate (0.03, 0.1, 0.3 or 3.0 mg/kg IP) followed 30 minutes 
later by saline or morphine sulfate (1.0, 3.0, 10.0, 30.0 or 100 
mg/kg SC). MK-801 was purchased from Research Biochemicals 
Incorporated and morphine from the University of Michigan Hos- 
pital Pharmacy. Following injection animals were placed in plas- 
tic boxes and observed for gross behavioral effects. Catalepsy 
was determined as follows: 60 minutes following the morphine 
injection the rat was grasped gently around the back by the ex- 
perimenter, lifted from the box, and gently inverted so that the 
legs were pointed toward the ceiling. A rat was considered cata- 
leptic if it maintained a completely rigid posture, and did not at- 
tempt to right. Results are presented as percent of animals cataleptic 
at 60 minutes after morphine injection (catalepsy), and the per- 
cent of animals found dead within 12 hours following injections 
(lethality). 
RESULTS 
In saline-pretreated rats, no catalepsy was observed at doses 
of morphine up to 10 mg/kg. At 30 mg/kg 3 of 6 animals (50%) 
were cataleptic, while at 100 mg/kg 6/6 (100%) were cataleptic; 
the EDso for morphine-induced catalepsy thus was approximately 
30 mg/kg (Fig. 1). Animals treated with MK-801 (0.03 to 3.0 
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FIG. 1. Potentiation of morphine-induced catalepsy by MK-801. Animals 
were treated with saline (open squares) or MK-801 (0.3 mg/kg IP; closed 
triangles), followed 30 minutes later by morphine (1.0-100 mg/kg SC). 
Effects are represented as the percent of animals cataleptic 60 minutes 
following morphine treatment. The dose of morphine is shown on a log- 
arithmic scale on the abscissa. *All 6 animals treated with 0.3 mg/kg 
MK-801 and 30 mg/kg morphine, and 3 of 24 animals treated with 0.3 
mg/kg MK-801 and 10 mg/kg morphine died before the test for catalepsy. 
Since these animals were not tested, their data is not shown; however, it 
is assumed that these animals did become cataleptic, since this was uni- 
formly observed for other animals treated with either saline and morphine 
or MK-801 and morphine prior to death. 
mg/kg), followed by saline, showed no catalepsy. At 0.3 mg/kg 
MK-801 produced head weaving, body rolling and ataxia as pre- 
viously described (6,14), and at 3.0 mg/kg, rather than rigid, an- 
imals appeared to have a lack of muscle tone, becoming quite 
limp. Potent interactions occurred when MK-801 was adminis- 
tered prior to morphine treatment. At a dose of 0.3 mg/kg, MK- 
801 caused a shift to the left in the cataleptic actions of morphine, 
decreasing the EDso from approximately 30 mg/kg to less than 10 
mg/kg (Fig. 1). Lower doses of MK-801 did not affect morphine 
catalepsy. The catalepsy seen in rats treated with MK-801 and 
morphine was very similar to that seen in rats treated with high 
doses of morphine. The animals showed a high degree of muscu- 
lar rigidity with the tail extended stiffly, and showed little or no 
movement. 
MK-801 also increased the lethal effects of morphine. Mor- 
phine, following saline pretreatment, produced no deaths at doses 
up to 10 mg/kg. At 30 mg/kg 2 of 6 animals (33%) died, while 
at 100 mg/kg 3 of 6 (50%) died (Fig. 2). No deaths were ob- 
served in any animals treated with MK-801, followed by saline, 
at doses up to 3.0 mg/kg, the highest dose examined. When MK- 
801 (0.3 mg/kg) was administered prior to morphine treatment, a 
dramatic shift in the lethality for morphine occurred (Fig. 2); 11/24 
animals (46%) died following 10 mg/kg morphine, and 6/6 (100% ) 
died following 30 mg/kg morphine. Although precise LDso'S were 
not determined, the present data suggest a nearly 10-fold shift in- 
the LDso for morphine in the presence of 0.3 mg/kg of MK-801, 
from approximately 100 mg/kg to approximately 10 mg/kg. Lower 
doses of MK-801 did not affect morphine lethality. Catalepsy and 
lethality produced in animals treated with the combination of 
morphine and MK-801 was prevented by naloxone (2.0 mg/kg 
SC; data not shown). 
DISCUSSION 
The present studies demonstrate that the noncompetitive 
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FIG. 2. Potentiation of morphine lethality by MK-801. Animals were 
treated with saline (open squares) or MK-801 (0.3 mg/kg IP; closed tri- 
angles), followed 30 minutes later by morphine (1.0-100 mg/kg SC). Ef- 
fects are represented as the percent of animals found dead within 12 hours 
following injections. The dose of morphine is shown on a logarithmic 
scale on the abscissa. 
phine-induced catalepsy and lethality. The observed potentiation 
was quite striking; a dose of 0.3 mg/kg of MK-801 shifted the 
EDso for morphine-induced catalepsy by over 3-fold, and the LDso 
for morphine by approximately 10-fold. Lower doses of MK-801 
did not increase morphine-induced catalepsy or lethality. This in- 
teraction thus appears to occur at relatively high doses of MK-801 
and morphine. While MK-801 potentiates morphine-induced cat- 
alepsy and lethality, this drug antagonizes morphine tolerance and 
dependence, and has no effect on morphine analgesia (15). The 
effects of MK-801 on the actions of morphine are, therefore, be- 
haviorally quite specific. NMDA receptor antagonists have previ- 
ously been reported to interact with several drugs broadly classified 
as CNS depressants. For example, MK-801, phencyclidine and 
ketamine have been observed to increase the effects of general 
anesthetics (5,17); phencyclidine and ketamine have been ob- 
served to interact with morphine (1,10); and phencyclidine has 
been observed to potentiate the effects of ethanol (2,17). It thus 
appears that noncompetitive NMDA receptor antagonists have the 
ability to increase the CNS depressant actions, including the tox- 
icity, of several different drugs. 
The present findings may help to resolve an important conflict 
in the literature regarding the behavioral effects of MK-801. While 
some studies have reported cataleptic actions of this drug (9, 11, 
18), others have reported no such effects (6,14). Importantly, 
each of the studies finding cataleptic actions of MK-801 in ro- 
dents injected the drug in animals pretreated with a general anes- 
thetic, suggesting that the catalepsy resulted from an interaction 
between the MK-801 and the anesthetic, rather than from the 
MK-801 by itself. We observed no cataleptic actions of MK-801 
in the absence of morphine at doses up to 3.0 mg/kg. Doses up 
to 50 mg/kg have been injected in mice without producing cata- 
lepsy (5). The potentiation of morphine-induced catalepsy seen in 
the present studies with MK-801 is in stark contrast to the antag- 
onism of haloperidol-induced catalepsy reported by others (13). 
It, therefore, appears that MK-801 may either potentiate or antag- 
onize catalepsy, depending on the experimental procedure pro- 
ducing the catalepsy. This distinction may have important 
implications regarding the mechanisms involved in morphine- and 
haloperidol-induced catalepsy. Previous studies have emphasized 
the differences between the states produced by these drugs, char- 
acterizing the morphine-induced state as "catatonia" and the 
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haloperidol-induced state as "catalepsy" (12). 
The mechanisms responsible for the effects of MK-801 on 
morphine-induced catalepsy and lethality are presently unclear. 
Evidence suggests that the periaqueductal gray (PAG) region is 
the primary locus for the cataleptic actions of opioid compounds 
(12). However, recent studies have reported that striatal injec- 
tions of the NMDA receptor antagonist AP7 potentiate opioid-in- 
duced catalepsy (3). MK-801 may, therefore, act in either the 
PAG or the caudate-putamen (or both) to potentiate the cataleptic 
effects of opioid compounds. In regards to lethality, it is well es- 
tablished that the cause of death from morphine overdose is res- 
piratory arrest from actions at brainstem breathing control nuclei 
(7). Animals in the present experiments that died from combina- 
tions of morphine and MK-801 appeared very similar to those 
that died from high doses of morphine, becoming cataleptic and 
rigid, and showing signs of respiratory distress shortly prior to 
death. MK-801 may, therefore, act at the level of the brainstem 
to potentiate the respiratory depressant effects of morphine, pro- 
ducing deaths at doses of morphine that are not normally fatal. 
Although the above evidence suggests that different brain struc- 
tunes may be responsible for the cataleptic and lethal interac- 
tions between these drugs, a common site (or sites) cannot be 
ruled out. 
The widespread neural and behavioral effects of NMDA re- 
ceptor antagonists have led to suggestions that these drugs may be 
useful in a variety of clinical disorders. The present results, to- 
gether with previous findings, suggests that potent interactions 
may occur when these drugs are administered in the presence of 
CNS depressants. Therefore, appropriate caution should be used 
when MK-801 or other NMDA receptor antagonists are used in 
combination with opioids or other CNS depressants. More insid- 
iously, these findings suggest a potential danger for the coabuse 
of NMDA antagonists, such phencyclidine, and opiates, such as 
morphine, two classes of drug that are commonly abused. 
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